Regulatory Filing
Godavari Biorefineries Secures Japanese Patent for Cancer Treatment Compound
NSE
GODAVARIB
BSE
544279
Godavari Biorefineries Limited announced that the Japan Patent Office has granted a patent for its invention titled “5-Hydroxy-1,4-Naphthalenedione for Use in the Treatment of Cancer.” The patent relates to a novel class of compounds that demonstrated inhibitory effects against cancer and cancer stem cells, with reported efficacy across multiple cancer types including breast and prostate cancer.
PRICE-SENSITIVE TRIGGER
Event: Grant of patent by the Japan Patent Office for a cancer treatment compound.
Type: Regulatory Filing
Impact: Positive
Immediate Effect: Strengthens the company’s intellectual property portfolio and provides patent protection in Japan for its oncology-related innovation.
What Happened ?
Godavari Biorefineries informed stock exchanges that the Japan Patent Office has granted a patent covering “5-Hydroxy-1,4-Naphthalenedione for Use in the Treatment of Cancer.” According to the company, the patented invention relates to a novel class of compounds that exhibit strong inhibitory effects on cancer cells and cancer stem cells. The company stated that the compounds have demonstrated significant efficacy against multiple cancer indications, including breast and prostate cancer.
Key Details
Patent Grant and Technology Scope:
- Patent granted by the Japan Patent Office.
- Patent title: “5-Hydroxy-1,4-Naphthalenedione for Use in the Treatment of Cancer.”
- Japanese Patent Number: 7869786.
- Registration Date: May 26, 2026.
- The patent originates from application number 2023-525533.
- The patented technology relates to a novel class of compounds targeting cancer and cancer stem cells.
- The company highlighted efficacy against multiple cancer types, including breast cancer and prostate cancer.
- Patent protection extends the company’s intellectual property coverage in a major pharmaceutical market.
Note:
- The grant represents regulatory recognition of the underlying invention and may support future research, licensing, commercialization, or strategic development initiatives in oncology-related applications.
Risk Analysis
Summary:
- While the patent strengthens intellectual property protection, commercial success remains dependent on further development, validation, regulatory approvals, and potential market adoption.
Key Risks:
- Patent protection does not guarantee commercial revenue generation.
- Clinical development and regulatory pathways may require significant time and investment.
- Future commercialization outcomes remain subject to scientific and regulatory milestones.
- No timeline for product development or commercialization has been disclosed.
Worst Case Scenario:
- The patented technology may not translate into commercially viable products despite receiving intellectual property protection.
Risk Level: Medium
Company Commentary
- The Japan Patent Office has granted the company’s patent titled “5-Hydroxy-1,4-Naphthalenedione for Use in the Treatment of Cancer.”
- The patent covers a novel class of compounds exhibiting strong inhibitory effects on cancer and cancer stem cells.
- The company stated that the invention has demonstrated significant efficacy against multiple cancer types, including breast and prostate cancer.
- A copy of the patent grant certificate was attached to the exchange filing for reference.
Official Exchange Filing: Godavari Biorefineries Limited
